Adaptive Methods: When and How Should They be Used in Clinical Trials?

被引:0
|
作者
Porcher, Raphael [2 ]
Lecocq, Brigitte [1 ]
Vray, Muriel [3 ]
机构
[1] Novartis Pharma SAS, Lab Novartis, F-92506 Rueil Malmaison, France
[2] Univ Paris Diderot, Hop St Louis, Paris, France
[3] Inst Pasteur, Paris, France
来源
THERAPIE | 2011年 / 66卷 / 04期
关键词
interim analysis; adaptative trial; experimental design; amendement; treatment selection; CONTINUAL REASSESSMENT METHOD; HYPOTHESES SELECTION; DRUG DEVELOPMENT; 2-STAGE DESIGNS; PHASE-I; INTERIM; SURVIVAL; POWER;
D O I
10.2515/therapie/2011044
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adaptive clinical trial designs are defined as designs that use data cumulated during trial to possibly modify certain aspects without compromising the validity and integrity of the said trial. Compared to more traditional trials, in theory, adaptive designs allow the same information to be generated but in a more efficient manner. The advantages and limits of this type of design together with the weight of the constraints, in particular of a logistic nature, that their use implies, differ depending on whether the trial is exploratory or confirmatory with a view to registration. One of the key elements ensuring trial integrity is the involvement of an independent committee to determine adaptations in terms of experimental design during the study. Adaptive methods for clinical trials are appealing and may be accepted by the relevant authorities. However, the constraints that they impose must be determined well in advance.
引用
收藏
页码:319 / 326
页数:8
相关论文
共 50 条
  • [1] Adaptive methods: when and how to use them in clinical trials?
    Porcher, Raphael
    Lecocq, Brigitte
    Vray, Muriel
    THERAPIE, 2011, 66 (04): : 309 - 317
  • [2] Composite outcomes in clinical trials: what are they and when should they be used?
    Heddle, Nancy M.
    Cook, Richard J.
    TRANSFUSION, 2011, 51 (01) : 11 - 13
  • [3] Methods for susceptibility testing in anaerobes: When and how they should be used
    Bianchini, HM
    ANAEROBE, 1999, 5 (3-4) : 417 - 420
  • [4] Patients should be informed when AI systems are used in clinical trials
    Subha Perni
    Lisa Soleymani Lehmann
    Danielle S. Bitterman
    Nature Medicine, 2023, 29 : 1890 - 1891
  • [5] Patients should be informed when AI systems are used in clinical trials
    Perni, Subha
    Lehmann, Lisa Soleymani
    Bitterman, Danielle S.
    NATURE MEDICINE, 2023, 29 (08) : 1890 - 1891
  • [6] THE ANTIANDROGENS - WHEN AND HOW THEY SHOULD BE USED
    SAWAYA, ME
    HORDINSKY, MK
    DERMATOLOGIC CLINICS, 1993, 11 (01) : 65 - 72
  • [7] When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts
    Jakobsen, Janus Christian
    Gluud, Christian
    Wetterslev, Jorn
    Winkel, Per
    BMC MEDICAL RESEARCH METHODOLOGY, 2017, 17
  • [8] When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts
    Janus Christian Jakobsen
    Christian Gluud
    Jørn Wetterslev
    Per Winkel
    BMC Medical Research Methodology, 17
  • [9] ACITRETIN AND ETRETINATE - HOW AND WHEN THEY SHOULD BE USED
    GEIGER, JM
    SAURAT, JH
    DERMATOLOGIC CLINICS, 1993, 11 (01) : 117 - 129